Authors

Latest:

Reflections of an Inaugural Gynecologic Oncology Fellow

Nujsaubnusi Vue, MD, shares reflections on the challenges, successes, and failures that she's encountered thus far as an inaugural fellow.

Daniel Sherbenou, MD, PhD

Latest:

Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple Myeloma

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Jared Kaltwasser

Latest:

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Lu Xie, MD

Lu Xie, MD of Peking University People's Hospital, China.

Latest:

Dr Xie on the ARTEMIS-002 Study Investigating HS-20093 in Relapsed/Refractory Sarcomas

Lu Xie, MD, discusses the design of the phase 2 ARTEMIS-002 trial.

Kevin Diasti, MD

Latest:

Geography Should Not Be Destiny

To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.

Andrei Gafita, MD

Latest:

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Steven J. Cohen, MD

Latest:

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Anne Chiang, MD, PhD, Yale Cancer Center

Latest:

Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.

Ryan D. Cassaday, MD, University of Washington/Fred Hutch

Latest:

Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.

Brandon Blue, MD

Latest:

How Passion for Healing and Health Care Equity Expands Access to Innovative Therapies: With D. Ross Camidge, MD, PhD; and Brandon Blue, MD

Drs Camidge and Blue discussed Dr Blue’s journey into practicing medicine, and speciaffly how he settled on treating malignant hematologic conditions.

Ernest S. Han, MD, PhD

Latest:

Dr Han on the Use of HIPEC in Ovarian Cancer

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Praveen Ramakrishnan, MD, MS

Latest:

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Stephen Freedland, MD, Cedars-Sinai Medical Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Wenxin Xu, MD

Latest:

Dr Xu on Changes in Systemic Therapy in RCC

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Bradley J. Monk, MD, FACS, FACOG

Latest:

Treatment Strategies in Non-Responders to Chemotherapy

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Benjamin Creelan, MD

Navid Redjal, MD, FAANS

Latest:

Dr. Redjal on Technological Advances in Neurosurgical Oncology

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Steven Vernino, MD, PhD

Latest:

Clinical Pearls and the Future of LEMS

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Mansi Dalal, MD

Latest:

Dr. Dalal on Graft Failure in Pediatric Non-malignant Disorders

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Deba Sarma, MD

Deba Sarma, MD, is a breast surgical oncologist at the Atrium Health Levine Cancer Institute and an assistant professor of surgery at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Latest:

Dr Sarma on the Current Role of Sentinel Node Biopsies in Breast Cancer

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.